✦ LIBER ✦

Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial

✍ Scribed by Burnett, A K; Hills, R K; Grimwade, D; Jovanovic, J V; Craig, J; McMullin, M F; Kell, J; Wheatley, K; Yin, J A L; Hunter, A; Milligan, D; Russell, N H

Book ID: 120011936
Publisher: Nature Publishing Group
Year: 2012
Tongue: English
Weight: 491 KB
Volume: 27
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2012.360

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Addition of Radiation to Chemotherap

The Addition of Radiation to Chemotherapy does not Improve Outcome When Compared to Chemotherapy in the Treatment of Resected Pancreas Cancer: The Results of a Single-Institution Experience

✍ Martin, Ludmila Katherine; Luu, Dai Chu; Li, Xiaobai; Muscarella, Peter; Christo 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 302 KB

Randomised comparison of addition of aut

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial

✍ Alan K Burnett; Anthony H Goldstone; Richard MF Stevens; Ian M Hann; John KH Ree 📂 Article 📅 1998 🏛 The Lancet 🌐 English ⚖ 113 KB

Does the addition of a pharmacist transi

Does the addition of a pharmacist transition coordinator improve evidence-based medication management and health outcomes in older adults moving from the hospital to a long-term care facility? Results of a randomized, controlled trial

✍ Maria Crotty; Debra Rowett; Lisa Spurling; Lynne C. Giles; Paddy A. Phillips 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 622 KB

Adding arabinosylcytosine to idarubicin

Adding arabinosylcytosine to idarubicin induction therapy may not improve survival for people with newly diagnosed acute promyelocytic leukaemia: Abstracted from: Avvisati G, Petti M, Lo-Coco F et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study. LAP 0389 with 7 years of minimal follow-up. Blood 2002; 100 (9): 3141–6.

✍ Elihu Estey; Miguel A. Sanz 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 77 KB